Aureka Open-Sourced Antibody AI That Beats AlphaFold 3; Closes $100M Drug Discovery Round
Aureka Biotechnologies, a three-year-old TechBio startup co-headquartered in Laguna Hills, California, and Shanghai, closed a $100 million Series B financing round on August 10, 2026 — backed by a model whose independent benchmarks show it clearing 70% …